Effect of tranexamic acid on rebleeding, mortality, and hydrocephalus in patients with aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis.
Mohammed Maan Al-Salihi, Ahmed Abd Elazim, Maryam Sabah Al-Jebur, Ram Saha, Farhan Siddiq, Ali Ayyad, Adnan I Qureshi
{"title":"Effect of tranexamic acid on rebleeding, mortality, and hydrocephalus in patients with aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis.","authors":"Mohammed Maan Al-Salihi, Ahmed Abd Elazim, Maryam Sabah Al-Jebur, Ram Saha, Farhan Siddiq, Ali Ayyad, Adnan I Qureshi","doi":"10.1016/j.jocn.2025.111189","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The therapeutic benefit of tranexamic acid (TXA) in patients with aneurysmal subarachnoid hemorrhage (aSAH) remains controversial. We evaluated the efficacy and safety of TXA in aSAH patients by performing a comprehensive meta-analysis of randomized controlled trials (RCTs).</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis of RCTs comparing TXA with either placebo or standard care in aSAH patients. A comprehensive literature search was performed across PubMed, EMBASE, Web of Science, Cochrane Library, and Scopus from inception to July 2024. Outcomes of interest included rebleeding, mortality, functional outcomes, and delayed cerebral ischemia (DCI). Subgroup analyses were performed based on publication date and TXA administration duration.</p><p><strong>Results: </strong>Thirteen RCTs were included in our study. TXA significantly reduced rebleeding rates (relative risk [RR] 0.61; 95 % confidence interval [CI] 0.51-0.74, P < 0.00001) but did not affect mortality (RR 0.99; 95 % CI 0.86-1.13, P = 0.84) or good clinical outcomes (RR 0.98; 95 % CI 0.93-1.05, P = 0.63). TXA use was associated with increased occurrence of hydrocephalus (RR 1.12; 95 % CI 1.01-1.23, P = 0.03) but not DCI (RR 1.00; 95 % CI 0.84-1.20, P = 0.96). Subgroup analyses suggested greater rebleeding reduction with longer TXA administration (≥1 week) and in more recent studies (post-2000).</p><p><strong>Conclusions: </strong>TXA reduces rebleeding in aSAH but does not improve survival or functional outcomes. Its routine use in aSAH is not supported by current evidence.</p>","PeriodicalId":15487,"journal":{"name":"Journal of Clinical Neuroscience","volume":"135 ","pages":"111189"},"PeriodicalIF":1.9000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jocn.2025.111189","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The therapeutic benefit of tranexamic acid (TXA) in patients with aneurysmal subarachnoid hemorrhage (aSAH) remains controversial. We evaluated the efficacy and safety of TXA in aSAH patients by performing a comprehensive meta-analysis of randomized controlled trials (RCTs).
Methods: We conducted a systematic review and meta-analysis of RCTs comparing TXA with either placebo or standard care in aSAH patients. A comprehensive literature search was performed across PubMed, EMBASE, Web of Science, Cochrane Library, and Scopus from inception to July 2024. Outcomes of interest included rebleeding, mortality, functional outcomes, and delayed cerebral ischemia (DCI). Subgroup analyses were performed based on publication date and TXA administration duration.
Results: Thirteen RCTs were included in our study. TXA significantly reduced rebleeding rates (relative risk [RR] 0.61; 95 % confidence interval [CI] 0.51-0.74, P < 0.00001) but did not affect mortality (RR 0.99; 95 % CI 0.86-1.13, P = 0.84) or good clinical outcomes (RR 0.98; 95 % CI 0.93-1.05, P = 0.63). TXA use was associated with increased occurrence of hydrocephalus (RR 1.12; 95 % CI 1.01-1.23, P = 0.03) but not DCI (RR 1.00; 95 % CI 0.84-1.20, P = 0.96). Subgroup analyses suggested greater rebleeding reduction with longer TXA administration (≥1 week) and in more recent studies (post-2000).
Conclusions: TXA reduces rebleeding in aSAH but does not improve survival or functional outcomes. Its routine use in aSAH is not supported by current evidence.
期刊介绍：
This International journal, Journal of Clinical Neuroscience, publishes articles on clinical neurosurgery and neurology and the related neurosciences such as neuro-pathology, neuro-radiology, neuro-ophthalmology and neuro-physiology.
The journal has a broad International perspective, and emphasises the advances occurring in Asia, the Pacific Rim region, Europe and North America. The Journal acts as a focus for publication of major clinical and laboratory research, as well as publishing solicited manuscripts on specific subjects from experts, case reports and other information of interest to clinicians working in the clinical neurosciences.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
